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Stem Cell Transplantation in the Treatment of
Follicular LymphomaAmong the primary objectives of the American
Society for Blood and Marrow Transplantation are to:
 Define commonly accepted medical and evidence-
based practice
 Develop standards of medical care for autologous
and allogeneic transplants
 Provide recommendations for physicians, patients,
and third-party payers on the role of transplantation
as a therapeutic approach.
Toward this end, in 1999, the Society began spon-
soring evidence-based reviews of the scientific and
medical literature to document when blood and
marrow transplantation is indicated in the treatment
of selected diseases.GOALS
The goals of the evidence-based reviews are to:
 Determine which disease will be the subject of each
review, establish the focus for each review, and
develop a list of questions to be addressed.
 Assemble and critically evaluate all valid, peer-
reviewed evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplanta-
tion (SCT) related to the disease.
 Provide treatment recommendations based on the
available evidence.
 Identify discrepancies in study design or methodol-
ogy among published studies that may impact the
quality of the evidence.
 Identify areas of needed research.TREATMENT RECOMMENDATIONS
The following treatment recommendations are of-
fered for the role of SCT as treatment for follicular
lymphoma (FL), and are based on consensus reached
by an expert panel1 following a systematic review of
the literature.2/$36.00
6/j.bbmt.2010.10.001Autologous SCT versus Nontransplantation
Therapy
1. Based on prerituximab data, there is a statistically
significant improvement in overall survival (OS)
and progression-free survival (PFS) using autol-
ogous SCT as salvage therapy.
2. With only one retrospective study, there are insuf-
ficient data tomake a recommendation on the use of
autologous SCT versus nontransplantation therapy
as salvage treatment for patients who have had
rituximab as part of their salvage therapy.
3. Autologous SCT is recommended for transformed
FL based on expert opinion and accepted clinical
practice.
4. Although there is consistent improvement in PFS
and event-free survival (EFS) with autologous SCT,
it is not recommended asfirst-line treatment formost
patients because of no significant improvement in
OS, a higher incidence of secondary myelodysplastic
syndrome (MDS) and acute myeloid leukemia
(AML), and a lack of comparative data with
rituximab-containing regimens. Longer follow-up
may be needed to identify differences in OS.Autologous SCT: Timing and Protocol
1. There are insufficient data to make a recommenda-
tion on the efficacy of autologous SCT as first-line
versus salvage therapy.
2. Because of conflicting data, a recommendation can-
not be made on the use of rituximab as part of first-
line or salvage regimens prior to autologous SCT.
3. There are insufficient data to make a recommenda-
tion regarding purging of autologous SCT.
4. There are insufficient data to recommend one high-
dose regimen over another. Total-body irradiation
(TBI)-containing regimens are usually avoided be-
cause of a concern for the risk of secondaryMDS or
AML.Autologous versus Allogeneic SCT
1. There are insufficient data comparing autologous
SCT and myeloablative allogeneic SCT to
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to have a survival benefit, but have competing risks.
Comparison of these two techniques is biased by
different patient selection criteria.
2. There are currently no data available to make
a recommendation regarding the use of reduced
intensity/nonmyeloablative allogeneic SCT versus
autologous SCT. Comparison of these two tech-
niques is biased by different patient selection criteria.Allogeneic SCT: Conditioning and Donor
Source
1. Reduced intensity conditioning (RIC) appears to be
an acceptable alternative approach in allogeneic
SCT based on one study and expert opinion.
2. There are insufficient data to recommend one con-
ditioning regimen over another for allogeneic SCT.
3. In allogeneic SCT, anHLA-matched unrelated do-
nor appears to be as effective as an HLA-matched
related donor using RIC based on expert opinion.AREAS OF NEEDED RESEARCH
After reviewing the evidence, the expert panel
identified the following important areas of needed
research in FL:
1. Rituximab-based therapy followed by autologous
SCT versus rituximab-based therapy without
SCT.
2. Post-autologous SCT rituximab maintenance
therapy versus no post-autologous SCT mainte-
nance rituximab.
3. Ex vivo–purged autologous SCT.
4. T cell–depleted allogeneic SCT.5. Comparison of matched-related versus matched-
unrelated or other alternative donor for allogeneic
SCT.
6. The efficacy and toxicity of reduced-intensity reg-
imens before autologous and allogeneic SCT.
7. Reduced intensity allogeneic SCT as salvage ther-
apy after failed autologous SCT.
8. Radioimmunotherapy as part of the preparatory
regimen for autologous SCT or reduced
intensity allogeneic SCT.
9. The impact of radioimmunotherapy and newer
agents (ie, bendamustine, rituximab, alemtuzu-
mab, fludarabine, etc.) on stem cell quality.
10. Identification of surrogate molecular markers pre-
SCT that are predictive of long-term survival in
FL patients.
11. The association of FLIPI score at diagnosis and at
SCT with prognosis in FL patients.
1Expert panel members and authors of the review are: Denise M.
Oliansky, Roswell Park Cancer Institute (RPCI), Buffalo, NY; Leo
I. Gordon, Northwestern University Feinberg School of Medicine
and the Robert H. Lurie Comprehensive Cancer Center, Chicago,
IL; Jerry King, Blue Cross and Blue Shield of Illinois, Chicago,
IL; Ginna Laport, Stanford University Medical Center, Stanford,
CA; John P. Leonard, Cornell University, Weill Medical College,
New York, NY; Peter McLaughlin, MD Anderson Cancer Center,
Houston, TX; Robert J. Soiffer, Dana Farber Cancer Institute, Bos-
ton, MA; Koen W. van Besien, University of Chicago, Department
of Medicine, Chicago, IL; Michael Werner, Lymphoma Research
Foundation, Chicago, IL; Roy B. Jones, MD Anderson Cancer Cen-
ter, Houston, TX; Philip L. McCarthy, Jr., RPCI, Theresa Hahn,
RPCI.
2Reference: Oliansky D, Gordon L, King J, et al. The role of cyto-
toxic therapy with hematopoietic stem cell transplantation in the
therapy of follicular lymphoma: an evidence-based review. Biol Blood
Marrow Transplant. 2010;16:443-468.
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